JP2008502589A - 抗ｉｇｆ−ｉ受容体抗体 - Google Patents

抗ｉｇｆ−ｉ受容体抗体 Download PDF

Info

Publication number
JP2008502589A
JP2008502589A JP2006543832A JP2006543832A JP2008502589A JP 2008502589 A JP2008502589 A JP 2008502589A JP 2006543832 A JP2006543832 A JP 2006543832A JP 2006543832 A JP2006543832 A JP 2006543832A JP 2008502589 A JP2008502589 A JP 2008502589A
Authority
JP
Japan
Prior art keywords
antibody
therapeutic agent
igf
receptor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006543832A
Other languages
English (en)
Japanese (ja)
Inventor
シン，ラジーヴァ
タヴァレス，ダニエル・ジェイ
ダグディジアン，ナンシー・イー
Original Assignee
イミュノジェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by イミュノジェン・インコーポレーテッド filed Critical イミュノジェン・インコーポレーテッド
Publication of JP2008502589A publication Critical patent/JP2008502589A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2006543832A 2003-12-08 2004-12-07 抗ｉｇｆ−ｉ受容体抗体 Pending JP2008502589A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
JP2008502589A true JP2008502589A (ja) 2008-01-31

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006543832A Pending JP2008502589A (ja) 2003-12-08 2004-12-07 抗ｉｇｆ−ｉ受容体抗体

Country Status (13)

Country Link
EP (1) EP1692176A4 (de)
JP (1) JP2008502589A (de)
KR (1) KR20070001883A (de)
CN (1) CN1886424A (de)
AU (1) AU2004303792A1 (de)
BR (1) BRPI0417406A (de)
CA (1) CA2548065A1 (de)
CR (1) CR8426A (de)
EA (1) EA009807B1 (de)
EC (1) ECSP066595A (de)
IL (1) IL174770A0 (de)
MX (1) MXPA06005540A (de)
NO (1) NO20063155L (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190067275A (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
JP2005533493A (ja) * 2002-06-14 2005-11-10 イムノージェン インコーポレーテッド 抗ｉｇｆ−ｉ受容体抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532685A (ja) * 1998-12-04 2002-10-02 ノバルティス アクチエンゲゼルシャフト 活性化ビトロネクチンレセプターαＶβ３をターゲティングするために有用な方法および組成物
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
JP2005533493A (ja) * 2002-06-14 2005-11-10 イムノージェン インコーポレーテッド 抗ｉｇｆ−ｉ受容体抗体

Also Published As

Publication number Publication date
AU2004303792A1 (en) 2005-07-07
CA2548065A1 (en) 2005-07-07
KR20070001883A (ko) 2007-01-04
ECSP066595A (es) 2006-10-17
CN1886424A (zh) 2006-12-27
NO20063155L (no) 2006-08-11
EP1692176A1 (de) 2006-08-23
IL174770A0 (en) 2006-08-20
EP1692176A4 (de) 2008-11-12
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
CR8426A (es) 2007-12-04
BRPI0417406A (pt) 2007-04-03

Similar Documents

Publication Publication Date Title
EP1532174B1 (de) Anti-igf-i-rezeptor-antikörper
US8034904B2 (en) Anti-IGF-I receptor antibody
JP7030689B2 (ja) 抗ｉｌ－２抗体ならびにその組成物及び使用
US8933202B2 (en) AXL antibodies
ES2800330T3 (es) Composiciones que comprenden Anticuerpos anti-IGF-1R y Métodos para obtener dichos Anticuerpos
EP1819358B1 (de) Antikörper gegen vaskulären endothel-wachstumsfaktor-rezeptor-1
JP2008502589A (ja) 抗ｉｇｆ−ｉ受容体抗体
US20150152193A1 (en) Axl antibodies
KR20050021001A (ko) 인간 인슐린-유사 성장인자-i 수용체 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110706